Important:
Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online. Please note that we are no longer producing new clinical podcasts.
UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.
Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.
This is the complete archive for the UpToDate Clinical Talk Podcasts.
Partially closed loop glucose monitoring in children and adolescents with type 1 diabetes
Date Released: Apr 4 2018
This episode features Dr. Joseph Wolfsdorf discussing advances in devices to manage children and adolescents with type 1 diabetes. Dr. Sadhna Vora hosts.
Dr. Wolfsdorf is a Professor of Pediatrics at Harvard Medical School and Director of the Diabetes Program at Boston Children's Hospital. He is also Section Editor in Pediatric Endocrinology at UpToDate.- Abraham MB, Nicholas JA, Smith GJ, et al. Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-term Randomized Controlled Trial in Adolescents With Type 1 Diabetes. Diabetes Care 2018; 41:303.
Joseph Wolfsdorf, MB, BCh Nothing to disclose
Third dose of MMR vaccine for prevention of mumps in an outbreak setting
Date Released: Mar 28 2018
This episode features Dr. Sheldon Kaplan discussing the use of a third dose of the MMR vaccine for the prevention of mumps in an outbreak setting. Dr. Jennifer Mitty hosts.
Dr. Kaplan is Professor of Pediatrics and head of the Pediatric Infectious Disease section at Baylor College of Medicine, and he is Chief of the Infectious Disease service and head of the Department of Pediatric Medicine at Texas Children’s Hospital in Houston.Segment on third dose of MMR vaccine for prevention of mumps in an outbreak setting (Dr. Kaplan):
- Marin M, Marlow M, Moore KL, et al. Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. MMWR Morb Mortal Wkly Rep 2018; 67:33.
- Cardemil CV, Dahl RM, James L, et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N Engl J Med 2017; 377:947
Sheldon Kaplan, MD Grant/Research/Clinical Trial Support: Pfizer [Streptococcus pneumonia (PCV13, linezolid)]; Merck [Staphylococcus aureus (Tedizolid)]; Allergen [Osteomyelitis (Ceftaroline)]. Consultant/Advisory Boards: Pfizer [Staphylococcus aureus (vaccine development); linezolid]. Other Financial Interest: Pfizer [Speaker on PCV13, linezolid]; Medscapre [Video discussion on bacterial meningitis]; Elsevier [Co-editor (Feigin and Cherry Textbook of Pediatric Infectious Diseases)].
Naltrexone versus buprenorphine for opioid use disorder
Date Released: Mar 21 2018
This episode features Dr. Andrew Saxon discussing treatments for opioid use disorder. Dr. Jennifer Mitty hosts.
Dr. Saxon is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington in Seattle, and he is Chair of the American Psychiatric Association’s Council on Addiction Psychiatry.Segment on naltrexone versus buprenorphine for opioid use disorder (Dr. Saxon):
- Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391:309.
- Tanum L, Solli KK, Latif ZE, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry 2017; 74:1197.
Andrew Saxon, MD Grant/Research/Clinical Trial Support: Medicasafe [Medication dispensing]. Consultant/Advisory Boards: Neurocrine Biosciences [Tardive dyskinesia (Valbenazine)].
Monoclonal antibodies to prevent migraine; Oral fecal microbiota transplant for C. diff infection
Date Released: Mar 7 2018
Today’s episode of UpToDate Talk features Dr. Jerry Swanson discussing novel monoclonal antibody therapies to prevent migraines, and Dr. Ciarán Kelly discussing oral fecal microbiota transplantation for the treatment of C. difficile infection. The second segment begins at 14:58. Dr. Nancy Sokol hosts.
Dr. Jerry Swanson is Professor of Neurology at the Mayo Clinic College of Medicine, where he's a consultant neurologist with a special interest in patients with headaches, including migraine. He is an UpToDate section editor in the neurology specialty.
Dr. Ciarán Kelly is Professor of Medicine at Harvard Medical School and Director of Gastroenterology Fellowship Training at Beth Israel Deaconess Medical Center in Boston. His clinical and research interests are in intestinal infection and inflammation. He is an UpToDate author of several topics covering C. difficile infection and celiac disease.Segment on monoclonal antibodies to prevent migraine (Dr. Swanson):
- Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 2017; 377:2113.
- Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377:2123.
Segment on oral fecal microbiota transplant for C. diff infection (Dr. Kelly):
- Kao D, Roach B, Silva M, et al. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA 2017; 318:1985.
Jerry Swanson, MD, MHPE Nothing to disclose
Ciarán Kelly, MD Consultant/Advisory Boards: Cellimmune [Celiac disease (Immune therapy in development)]; Cour Pharmaceuticals [Celiac disease (Immune therapy in development)]; Glutenostics [Celiac disease diagnostic]; Immunogenx [Celiac disease (Glutenase therapy in development)]; Innovate [Celiac disease (Larazotide acetate therapy in development)]; Merck [C difficile infection (Fidaxomicin, Bezlotoxumab)]; Seres Therapeutics [C difficile infection (prophylactic agent in development)]; Summit [C difficile infection (Ridinilazole in development)]; Synthetic Biologies [C difficile infection (Beta lactamase inhibitor in development)]; Takeda [Celiac disease (Therapies in development)]. Grant/Research/Clinical Trial Support: Aptalis [Celiac disease (Viokase pancrelipase)]; Institut Merieux [C difficile infection (ultrasensitive toxin assays); Merck [C difficile infection (Fidaxomicin, Bezlotoxumab); National Institutes of Health [C difficile (vaccine development, ultrasensitive toxin assays)]. Equity Ownership/Stock Options: Cour Pharmaceuticals [Celiac disease (Immune therapy in development)]; Glutenostics [Celiac disease diagnostic].